1. Incident tuberculosis disease in patients receiving biologic therapies in the Western Cape, South Africa from 2007 to 2018
   Tessa du Toit et al, 2020, BMC Infectious Diseases CrossRef
2. Effects of Tumor Necrosis Factor-alpha Inhibitors on the Incidence of Tuberculosis
   Hyun Jin Park et al, 2018, Korean Journal of Clinical Pharmacy CrossRef
3. Infliximab
   Karel Urbánek, 2017, Interní medicína pro praxi CrossRef
4. Calcium Complexes of Oxicams: New Dimensions in Rheumatoid Arthritis Treatment
   Aatika Sadia et al, 2022, Future Medicinal Chemistry CrossRef
5. A case report of probable ocular tuberculosis following biologics
   SudhaK Ganesh et al, 2021, Indian Journal of Ophthalmology - Case Reports CrossRef
6. Safety of Infliximab for the Eye Under Human T-Cell Leukemia Virus Type 1 Infectious Conditions in vitro
   Minami Uchida et al, 2019, Frontiers in Microbiology CrossRef
7. Relief of Symptoms by Early Administration of Infliximab in Patients with Suspected Spondyloarthritis: A Case Report
   Hyun Keun Lee et al, 2022, Soonchunhyang Medical Science CrossRef
8. Pathogenetic role of tumor necrosis factor (TNF-α) for the development of peritoneal tuberculosis in an experiment
   D. V. Plotkin et al, 2021, Acta Biomedica Scientifica CrossRef
9. Biologics in Focus: A Comprehensive Review of the Current Biological Therapies for Ulcerative Colitis in the United Arab Emirates (UAE)
   Ahmed El-Sayed et al, 2024, Gastrointestinal Disorders CrossRef
10. Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis
    Saurabh Kedia et al, 2020, American Journal of Gastroenterology CrossRef
11. Secondary immunodeficiencies and infectious considerations of biologic immunomodulatory therapies
    Laura Cannon et al, 2023, Annals of Allergy, Asthma & Immunology CrossRef
12. Protecting the most vulnerable: tuberculosis in immunocompromised individuals
    Egídio Torrado et al, 2023, The Challenge of Tuberculosis in the 21st Century CrossRef
13. Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
    Filiz Akyuz et al, 2019, European Journal of Gastroenterology & Hepatology CrossRef
14. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
    Simon Tiberi et al, 2018, The Lancet Infectious Diseases CrossRef
15. Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn’s Disease on Ustekinumab: A Nationwide Real-World Study
    Rongbei Liu et al, 2024, Inflammatory Bowel Diseases CrossRef
16. Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti‐TNF therapy in a tuberculosis endemic region
    Lingna Ye et al, 2021, Alimentary Pharmacology & Therapeutics CrossRef
17. Management of Specific Clinical Profiles in Axial Spondyloarthritis: An Expert’s Document Based on a Systematic Literature Review and Extended Delphi Process
    Rosario García-Vicuña et al, 2023, Rheumatology and Therapy CrossRef
18. Miliary tuberculosis presenting as a choroidal mass and a tuberculosis screening review
    Adam M. Kase et al, 2018, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases CrossRef
19. COVID-19-associated opportunistic infections: a snapshot on the current reports
    Amir Abdoli et al, 2021, Clinical and Experimental Medicine CrossRef
20. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
    Joshua S. Davis et al, 2020, Clinical Microbiology Reviews CrossRef